Nivolumab did not improve overall survival in patients with advanced hepatocellular carcinoma
1. The median overall survival for nivolumab was 16.4 months and for sorafenib was 14.7 months 2. Patients receiving nivolumab ...
Tag: Nivolumab
Nivolumab is a potential treatment option for patients with relapsing malignant mesothelioma
1. Overall survival was 6.9 months in the placebo group and 10.2 months in the nivolumab group. 2. Progression free ...
#VisualAbstract: Greater immunosuppression is associated with worse outcomes in patients with advanced melanoma receiving ipilimumab and anti-PD-1 therapy
Click to read the study in the European Journal of Cancer.
Adjunctive nivolumab reduces risk of death and progression of gastric adenocarcinoma compared to chemotherapy alone
1. Overall survival and progression-free survival were higher for patients on nivolumab plus chemotherapy compared to chemotherapy alone. 2. Severe ...
#VisualAbstract: Ipilimumab plus anti-PD-1 therapy is effective in patients with anti-PD-L1 resistant metastatic melanoma
Click to read the study in The Lancet Oncology.
#VisualAbstract: Liver metastases and LDH levels may be superior prognostic biomarkers for patients with metastatic melanoma
Click to read the study in JAMA Oncology.
#VisualAbstract: Combined anti-PD-1 and anti-CTLA-4 blockade improves survival among patients with BRAF-mutated melanoma and elevated LDH
Click to read the study in the European Journal of Cancer.
Nivolumab in resected esophageal or gastroesophageal junction cancer improved survival
1. Adjuvant nivolumab significantly improved disease-free survival compared to placebo among patients with resected esophageal or gastroesophageal junction cancer. 2. ...
